2007
CAMELIA: a new international registry for patients with chronic myeloid leukemia
FABER, Edgar; Jaroslava VOGLOVÁ; Vladimír KOZA; Pavol KOTOUČEK; Ľudmila DEMETROVIČOVÁ et al.Základní údaje
Originální název
CAMELIA: a new international registry for patients with chronic myeloid leukemia
Název česky
CAMELIA: nový mezinárodní registr pacientů s chronickou myeloidní leukémií
Autoři
FABER, Edgar; Jaroslava VOGLOVÁ; Vladimír KOZA; Pavol KOTOUČEK; Ľudmila DEMETROVIČOVÁ; Elena TOTHOVÁ; Juraj CHUDEJ; Pavel ŽÁK; Marie JAROŠOVÁ; Eva DEMEČKOVÁ; Jan MUŽÍK; Ladislav DUŠEK a Karel INDRÁK
Vydání
BLOOD REVIEWS, 2007
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.922
Označené pro přenos do RIV
Ne
Organizační jednotka
Lékařská fakulta
ISSN
UT WoS
Klíčová slova anglicky
chronic myeloid leukemia - treatment - registry
Změněno: 29. 4. 2011 12:43, prof. RNDr. Luděk Bláha, Ph.D.
V originále
CAMELIA has been founded in 2005 as a collaborative project of Leukemia Section of Czech Society of Hematology and Institute for Biostatistics and Analyses of Masaryk University (IBA) in Brno as an observational registry for monitoring of incidence, diagnostic aspects, prognostic factors and treatment response of patients (pats) with CML. At present 10 major hematologic centers from Czech Republic and Slovakia are participating in the registry. Data on 566 pats were collected so far. Presentation describes well 430 defined pats with Ph-positive CML (229 male and 201 female at median age 50 years) diagnosed after 2000: 401 (93%) of them in chronic phase, 24 (6%) in acceleration and 5 (1%) in blastic phase. Of 303 pats treated with imatinib (IM) in the chronic phase of CML 240 (79%) achieved complete hematologic and 203 (67%) partial cytogenetic response. OS of pats treated with IM in advanced phase of CML was significantly shorter than of pats in chronic phase (p=0,003).
Česky
CAMELIA has been founded in 2005 as a collaborative project of Leukemia Section of Czech Society of Hematology and Institute for Biostatistics and Analyses of Masaryk University (IBA) in Brno as an observational registry for monitoring of incidence, diagnostic aspects, prognostic factors and treatment response of patients (pats) with CML. At present 10 major hematologic centers from Czech Republic and Slovakia are participating in the registry. Data on 566 pats were collected so far. Presentation describes well 430 defined pats with Ph-positive CML (229 male and 201 female at median age 50 years) diagnosed after 2000: 401 (93%) of them in chronic phase, 24 (6%) in acceleration and 5 (1%) in blastic phase. Of 303 pats treated with imatinib (IM) in the chronic phase of CML 240 (79%) achieved complete hematologic and 203 (67%) partial cytogenetic response. OS of pats treated with IM in advanced phase of CML was significantly shorter than of pats in chronic phase (p=0,003).
Návaznosti
| MSM0021622412, záměr |
|